Trinity BiotechTRIB -1.37%20 Gross Margin % is 40.84% as of Dec. 2025, which is 2% below its 10-year median of 41.69. GuruFocus rates TRIB with a GF Score™ of 20/100 and a GF Value™ of $0.73 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 805 Medical Devices & Instruments companies, Trinity Biotech ranks worse than 70.19% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Trinity Biotech had a gross margin of 40.84% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Trinity Biotech Gross Margin % Related Terms
Trinity Biotech Gross Margin % Historical Data
* Premium members only.
The historical data trend for Trinity Biotech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Trinity Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trinity Biotech Gross Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Trinity Biotech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Trinity Biotech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Trinity Biotech (TRIB) has a Gross Margin % of 40.84% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Trinity Biotech and its competitors. This is near median its historical median of 41.69. Over the past decade, Trinity Biotech's Gross Margin % has ranged from 27.62 to 47.64. According to the industry distribution chart, Trinity Biotech ranks #565 out of 805 companies in the Medical Devices & Instruments industry, placing it in the top 70.2%.
Is Trinity Biotech's Gross Margin % too high?
Trinity Biotech's current Gross Margin % of 40.84% is near median its 10-year median of 41.69. Over the past 10 years, this metric has ranged from a low of 27.62 to a high of 47.64. The Medical Devices & Instruments industry median Gross Margin % is 52.07. Trinity Biotech's value of 40.84% is 21.6% below this industry median. Based on the distribution chart, Trinity Biotech ranks #565 out of 805 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Trinity Biotech has a GF Score™ of 20/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's Gross Margin % compare to PMI and NXL?
According to the Medical Devices & Instruments industry distribution chart, Trinity Biotech ranks #565 out of 805 companies for Gross Margin %. This places Trinity Biotech in the lower half of its industry. The industry median Gross Margin % is 52.07. Trinity Biotech's value of 40.84% is 21.6% below this benchmark. Historically, Trinity Biotech's own Gross Margin % has ranged from 27.62 to 47.64 over the past decade. While the company's 10-year median is 41.69 vs. the industry median of 52.07, Trinity Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Devices & Instruments company?
The median Gross Margin % among Medical Devices & Instruments companies is 52.07, based on 805 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Trinity Biotech's current Gross Margin % of 40.84% is 21.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Trinity Biotech and its competitors. For the Medical Devices & Instruments industry, the median Gross Margin % is 52.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trinity Biotech's current Gross Margin % is 40.84%, which is near median its own 10-year median of 41.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Based on GuruFocus' analysis, Trinity Biotech (TRIB) is currently considered Possible Value Trap. The stock's GF Value™ is $0.73, compared to a current price of $0.35 — trading 52.7% below its estimated fair value. The current Gross Margin % is 40.84%, which is near median its 10-year median of 41.69 and 21.6% below the Medical Devices & Instruments industry median of 52.07. Trinity Biotech's overall GF Score™ is 20/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Trinity Biotech (TRIB), the current Gross Margin % is 40.84% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trinity Biotech (TRIB) Overvalued in 2026?
Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued.
The current stock price of $0.35 is trading 52.7% below its estimated GF Value™ of $0.73.
GuruFocus considers Trinity Biotech to be Possible Value Trap.
Key valuation signals for TRIB:
Gross Margin %: 40.84% (near median its 10-year median of 41.69)
GF Value™: $0.73 vs. price of $0.35 (52.7% below fair value)
Industry Position: 21.6% below the Medical Devices & Instruments median (#565 of 805)
No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
20GF Score
Get the complete analysis for TRIB
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TRIB has been successfully added to your 
